Boston Scientific (BSX) EBT Margin (2009 - 2026)

Boston Scientific has disclosed EBT Margin across 18 years of filings, most recently posting 22.33% for Q1 2026.

• EBT Margin for Q1 2026 came in at 22.33%, up 507.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.15% (up 403.0% YoY), and the FY2025 annual result was 16.86%, up 324.0% from the prior year.
• EBT Margin came in at 22.33% for Q1 2026 at Boston Scientific, up from 13.24% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 22.33% in Q1 2026 to a low of 5.16% in Q1 2022.
• The 5-year median for EBT Margin is 13.24% (2025), against an average of 13.89%.
• Across the five-year window, EBT Margin sank 874 bps in 2022 and surged 957 bps in 2023, its largest moves.
• Boston Scientific's EBT Margin stood at 12.21% in 2022, then increased by 11 bps to 13.56% in 2023, then fell by 5 bps to 12.83% in 2024, then advanced by 3 bps to 13.24% in 2025, then jumped by 69 bps to 22.33% in 2026.
• The last three EBT Margin figures came in at 22.33% (Q1 2026), 13.24% (Q4 2025), and 18.54% (Q3 2025), per Business Quant data.